Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
VTVT
VTVT
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
VTVT News
Roth Capital Initiates Buy Rating on vTv Therapeutics with $58 Price Target
Jan 23 2026
Benzinga
vTv Therapeutics Initiated with Buy Rating and $67 Price Target
Jan 05 2026
Benzinga
vTv Therapeutics Upgraded to Zacks Rank #2 (Buy) Reflecting Positive Earnings Outlook
Dec 24 2025
NASDAQ.COM
vTv Therapeutics Submits Phase 2 Study Protocol for Cadisegliatin in Type 2 Diabetes
Dec 18 2025
Globenewswire
vTv Therapeutics Submits Phase 2 Trial Protocol for Cadisegliatin in Type 2 Diabetes
Dec 18 2025
Newsfilter
Everything You Should Know About vTv Therapeutics (VTVT) Upgrade to Buy Rating
Nov 11 2025
NASDAQ.COM
vTv Therapeutics Files for Resale of 15.9 Million Class A Shares
Oct 03 2025
SeekingAlpha
vTv Therapeutics to Take Part in INNODIA Symposium During EASD 61st Annual Meeting
Sep 15 2025
Newsfilter
VTv Therapeutics Obtains $80 Million Through PIPE Financing
Sep 02 2025
NASDAQ.COM
HC Wainwright & Co. Reiterates Buy on vTv Therapeutics, Maintains $36 Price Target
Aug 13 2025
Benzinga
vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Aug 12 2025
Yahoo Finance
vTv Therapeutics to Participate in the H.C. Wainwright "HCW@Home" Series
Jun 11 2025
Newsfilter
vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin
May 19 2025
Newsfilter
This Couchbase Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Apr 09 2025
Benzinga
vTv Therapeutics reports Q4 EPS (55c) vs ($1.67) last year
Mar 20 2025
Business Insider
FDA Lifts Clinical Hold On vTv Therapeutics' Phase 3 Diabetes Trial, Stock Surges
Mar 17 2025
Benzinga
Show More News
